Alivus Life SciencesNSE:ALIVUS -0.70%83 Operating Margin % is 28.20% as of Mar. 2026, which is 2% below its 10-year median of 28.91. GuruFocus rates NSE:ALIVUS with a GF Score™ of 83/100 and a GF Value™ of ₹1,004.33 (Fairly Valued). The stock has 3 warning signs investors should review. Among 955 Drug Manufacturers companies, Alivus Life Sciences ranks better than 92.67% on this metric.
Alivus Life Sciences Ltd operating margin has been in a 5-year decline. The average rate of decline per year is -1.5%.
The historical rank and industry rank for Alivus Life Sciences's Operating Margin % or its related term are showing as below:
NSE:ALIVUS'
s Operating Margin % Range Over the Past 10 Years
Min: 26.06 Med: 28.91 Max: 30.18
Current: 28.29
NSE:ALIVUS's Operating Margin % is ranked better than 92.67% of 955
companies
in the Drug Manufacturers industry
Industry Median: 7.45
vs NSE:ALIVUS: 28.29
Alivus Life Sciences's 5-Year Average Operating Margin % Growth Rate was -1.50% per year.
Alivus Life Sciences (NSE:ALIVUS) Operating Margin % Explanation
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Alivus Life Sciences Operating Margin % Related Terms
Alivus Life Sciences Operating Margin % Historical Data
* Premium members only.
The historical data trend for Alivus Life Sciences's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Alivus Life Sciences's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alivus Life Sciences Operating Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alivus Life Sciences's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Alivus Life Sciences's Operating Margin % falls into.
Alivus Life Sciences Operating Margin % Calculation
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Alivus Life Sciences's Operating Margin % for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alivus Life Sciences (NSE:ALIVUS) has a Operating Margin % of 28.20% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Alivus Life Sciences and its competitors. This is near median its historical median of 28.91. Over the past decade, Alivus Life Sciences' Operating Margin % has ranged from 26.06 to 30.18. According to the industry distribution chart, Alivus Life Sciences ranks #70 out of 955 companies in the Drug Manufacturers industry, placing it in the top 7.3%.
Is Alivus Life Sciences' Operating Margin % too high?
Alivus Life Sciences' current Operating Margin % of 28.20% is near median its 10-year median of 28.91. Over the past 10 years, this metric has ranged from a low of 26.06 to a high of 30.18. The Drug Manufacturers industry median Operating Margin % is 7.45. Alivus Life Sciences' value of 28.20% is 278.5% above this industry median. Based on the distribution chart, Alivus Life Sciences ranks #70 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Alivus Life Sciences has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Alivus Life Sciences' Operating Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Alivus Life Sciences ranks #70 out of 955 companies for Operating Margin %. This places Alivus Life Sciences in the top 7% of its industry — outperforming the majority of peers. The industry median Operating Margin % is 7.45. Alivus Life Sciences' value of 28.20% is 278.5% above this benchmark. Historically, Alivus Life Sciences' own Operating Margin % has ranged from 26.06 to 30.18 over the past decade. While the company's 10-year median is 28.91 vs. the industry median of 7.45, Alivus Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Drug Manufacturers company?
The median Operating Margin % among Drug Manufacturers companies is 7.45, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alivus Life Sciences's current Operating Margin % of 28.20% is 278.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Alivus Life Sciences and its competitors. For the Drug Manufacturers industry, the median Operating Margin % is 7.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alivus Life Sciences's current Operating Margin % is 28.20%, which is near median its own 10-year median of 28.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alivus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Alivus Life Sciences (NSE:ALIVUS) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,004.33, compared to a current price of ₹1,108.30 — trading 10.4% above its estimated fair value. The current Operating Margin % is 28.20%, which is near median its 10-year median of 28.91 and 278.5% above the Drug Manufacturers industry median of 7.45. Alivus Life Sciences' overall GF Score™ is 83/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Alivus Life Sciences (NSE:ALIVUS), the current Operating Margin % is 28.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alivus Life Sciences (NSE:ALIVUS) Overvalued in 2026?
Based on GuruFocus' analysis, Alivus Life Sciences stock appears to be overvalued.
The current stock price of ₹1,108.30 is trading 10.4% above its estimated GF Value™ of ₹1,004.33.
GuruFocus considers Alivus Life Sciences to be Fairly Valued.
Key valuation signals for NSE:ALIVUS:
Operating Margin %: 28.20% (near median its 10-year median of 28.91)
GF Value™: ₹1,004.33 vs. price of ₹1,108.30 (10.4% above fair value)
Industry Position: 278.5% above the Drug Manufacturers median (#70 of 955)
No single metric tells the full story. See the NSE:ALIVUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alivus Life Sciences Ltd develops, manufactures, and supplies high-quality active pharmaceutical ingredients for cardiovascular disease, central nervous system disorders, pain management, diabetes, urology, gastrointestinal disorders, and other therapeutic areas.
83GF Score
Get the complete analysis for NSE:ALIVUS
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ALIVUS has been successfully added to your 
